ArticleEuropean journal of heart failure2020
Association between systolic ejection time and outcomes in heart failure by ejection fraction.
Article in European journal of heart failure, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 33 citations in OpenAlex.
- Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials.European journal of heart failure · 2020Trial
- CArdiovasculaR Outcomes Based Upon EjectIon Systolic TimE in Patients With ST Elevation Myocardial Infarction (ARISE-STEMI) Study.CJC open · 2025Article
- Association between cardiac time intervals and incident heart failure after acute coronary syndrome.The international journal of cardiovascular imaging · 2024Article
- Acute Biomechanical Effects of Empagliflozin on Living Isolated Human Heart Failure Myocardium.Cardiovascular drugs and therapy · 2024Article
- 1-Year Mortality Prediction through Artificial Intelligence Using Hemodynamic Trace Analysis among Patients with ST Elevation Myocardial Infarction.Medicina (Kaunas, Lithuania) · 2024Article
- Review
- Omecamtiv mecarbil in precision-cut living heart failure slices: A story of a double-edged sword.Journal of molecular and cellular cardiology plus · 2023Article
- An Image-Based Computational Fluid Dynamics Study of Mitral Regurgitation in Presence of Prolapse.Cardiovascular engineering and technology · 2023Article
- Association of Carotid-Femoral Pulse Wave Velocity and Ejection Duration with Target Organ Damage.Reviews in cardiovascular medicine · 2023Article
- Heart failure: an update from the last years and a look at the near future.ESC heart failure · 2022Review
- Heart Failure Medical Therapy: A Review for Structural/Interventional Cardiologists.Structural heart : the journal of the Heart Team · 2022Review
- A year in heart failure: an update of recent findings.ESC heart failure · 2021Review
- Overcoming the Limits of Ejection Fraction and Ventricular-Arterial Coupling in Heart Failure.Frontiers in cardiovascular medicine · 2021Article
- Heart failure in the last year: progress and perspective.ESC heart failure · 2020Review
- Systolic time intervals in patients with heart failure: time to teach new dogs old tricks.European journal of heart failure · 2020Article
- Analysis of cardiac dynamic global function.JRSM cardiovascular diseaseArticle
Corrections and comments
- Commented on by
Authors and funding
9 authors at 6 institutions in 1 country.
Funding
Abstract
aimsWorsening heart failure (HF) is associated with shorter left ventricular systolic ejection time (SET), but there are limited data describing the relationship between SET and clinical outcomes. Thus, the objective was to describe the association between SET and clinical outcomes in an ambulatory HF population irrespective of ejection fraction (EF). METHODS AND
resultsWe identified ambulatory patients with HF with reduced EF (HFrEF) and HF with preserved EF (HFpEF) who had an outpatient transthoracic echocardiogram performed between August 2008 and July 2010 at a tertiary referral centre. Multivariable logistic regression was used to evaluate the association between SET and 1-year outcomes. A total of 545 HF patients (171 HFrEF, 374 HFpEF) met eligibility criteria. Compared with HFpEF, HFrEF patients were younger [median age 60 years (25th-75th percentiles 50-69) vs. 64 years (25th-75th percentiles 53-74], with fewer females (30% vs. 56%) and a similar percentage of African Americans (36% vs. 35%). Median (25th-75th percentiles) EF with HFrEF was 30% (25-35%) and with HFpEF was 54% (48-58%). Median SET was shorter (280 ms vs. 315 ms, P < 0.001), median pre-ejection period was longer (114 ms vs. 89 ms, P < 0.001), and median relaxation time was shorter (78.7 ms vs. 93.3 ms, P < 0.001) among patients with HFrEF vs. HFpEF. Death or HF hospitalization occurred in 26.9% (n = 46) HFrEF and 11.8% (n = 44) HFpEF patients. After adjustment, longer SET was associated with lower odds of the composite of death or HF hospitalization at 1 year among HFrEF but not HFpEF patients.
conclusionLonger SET is independently associated with improved outcomes among HFrEF patients but not HFpEF patients, supporting a potential role for normalizing SET as a therapeutic strategy with systolic dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.